Carolyn Ines Rodriguez, MD
Psychiatry · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Rodriguez’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C138308 · Current
Licensed to practise in California · since 2015 · expires 2027-04-30 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$41 in 2025
| 2025 | 1 | 1 | None | $41 |
| 2023 | 1 | 2 | $2,658 | $2,751 |
| 2022 | 1 | 3 | $9,900 | $9,900 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| MicroTransponder | None | $41 | 1 payment
|
See the published payment
| MicroTransponder | Meals · 2025-01-15 | None | $41 |
See earlier years (2023, 2022)
2023: $2,751
| Biogen | Vumerity | $2,751 | 2 payments
|
2022: $9,900
| Biohaven Pharmaceutical Holding Company | None | $9,900 | 3 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biohaven Pharmaceutical Holding Company Ltd. · A Randomized Double-Blind Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder · 2022 | Their institution | $91,661 |
| Biohaven Pharmaceuticals, Inc. · A Multicenter 48-Week Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder · 2021 | Their institution | $13,716 |
| Biohaven Pharmaceutical Holding Company Ltd. · A Multicenter 48-Week Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder · 2022 | Their institution | $9,187 |
| Biohaven Pharmaceuticals, Inc. · A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder · 2020 | Their institution | $375 |
Professional record
- NPI
- 1043478266
- Licence
- CA C138308California C138308: Current · expires 2027-04-30
- Trained
- Harvard Medical School, 2004
- Group
- Stanford Health Care
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-05-23
- NPI last updated
- 2024-04-30
- NPI record certified
- 2024-04-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1051 Riverside Dr, New York, NY, 10032